Loading…
EVAX
Evaxion A/S
NASDAQ· Healthcare· Biotechnology· CUSIP 29970R303
$3.01-4.44%Price as of Aug 29, 18:45 UTC · updated once a day, after the close
Key metrics
- Market cap
- $25.1M
- P/E
- —
- Forward P/E
- —
- P/B
- 2.4x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.48
- ROE
- -109.86%
- Profit margin
- -115.54%
- Revenue growth
- —
- Beta
- 0.25
- 52-week high
- $12.15
- 52-week low
- $2.52
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.1% over 5Y.
today you would have $6.93▼ -99.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $4.77 | $4.22 | $34.30 | $88.75 | |
| P/S | 264.2x | 264.2x | 88.6x | 17806.8x | — |
| P/B | — | 116.7x | — | — | 258.0x |
| EPS | -$1.00 | -$10.00 | -$40.50 | -$49.00 | |
| Profit margin | -316.00% | -102.38% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| TXMDTherapeuticsMD, Inc. | $2.16 | — | 0.9x | — | -1.08% | $25M |
| DYAIDyadic International Inc | $0.61 | — | — | — | — | $24.6M |
| ATOSAtossa Therapeutics Inc | $2.58 | — | 1.0x | — | -89.23% | $25.75M |
| TVRDTvardi Therapeutics, Inc. | $1.82 |
About the company
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
- 46
- Horsholm, Denmark
Company description provided by Yahoo Finance.